

HOSPITAL OUTPATIENT – BILLING INFORMATION SHEET FOR IMLYGIC® (talimogene laherparepvec)

INDICATION

IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitations of use: IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.

Item	Revenue Code	Coding Information (HCPCS¹/CPT²/ICD-10-CM³)	Notes
IMLYGIC®	Medicare: 0636, drugs requiring detailed coding Other Payers: 0250, general pharmacy; OR 0636, if required by a given payer	J9325, injection, talimogene laherparepvec, 1 million plaque forming units (PFU)	<ul style="list-style-type: none"> Code effective for dates of service on or after 1/1/2017 IMLYGIC® is still eligible for separate payment under Medicare under the Hospital Outpatient Prospective Payment System (OPPS) C9472 should no longer be submitted for claims with dates of service on or after 1/1/2017 National Drug Code (NDC) billing requirements may vary by payer The NDC numbers for IMLYGIC® in the 11-digit format, are as follows⁴: <ul style="list-style-type: none"> - 1 million PFU per 1 mL vial (10⁶ PFU/mL) for the initial dose only: 55513-0078-01 - 100 million PFU per 1 mL vial (10⁸ PFU/mL) for the second and subsequent doses: 55513-0079-01
Administration	Appropriate revenue code for the cost center in which the service is performed	96405, chemotherapy administration; intralesional, up to and including 7 lesions OR 96406, chemotherapy administration; intralesional, more than 7 lesions	If ultrasound guidance is used, the following administration code may also be appropriate: 76942, ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation
Diagnosis/Condition	N/A	Appropriate ICD-10-CM code(s) for patient condition	Examples of ICD-10-CM codes: C43.0 – C43.9 Malignant melanoma

The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this section be considered a guarantee of coverage or reimbursement for any product or service.

Contact Amgen SupportPlus at 866-AMG-ASST (1-866-264-2778) or visit www.amgenassist.com/copay

IMPORTANT SAFETY INFORMATION

Contraindications

- Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
- Do not administer IMLYGIC® to pregnant patients.

Please see additional Important Safety Information on page 5.



HOSPITAL OUTPATIENT – SAMPLE CMS 1450 FOR THE INITIAL DOSE OF IMLYGIC®

For Dates of Service on or After 1/1/2017

1		2		3a PAT		4 TYPE													
8 PATIENT NAME				9 PATIENT ADDRESS															
10 BIRTHDATE		11 SEX		12 DATE		13 ADMISSION													
14 TYPE		15 SRC		16 DHR		17 STAT													
18		19		20		21													
31 OCCURRENCE DATE		32 OCCURRENCE DATE		33 OCCURRENCE DATE		34 OCCURRENCE DATE													
35 CODE		36 CODE		37 CODE		38 CODE													
PRODUCT CODE (Box 44) J9325 , injection, talimogene laherparepvec, per 1 million plaque forming units (PFU)																			
SERVICE UNITS (Box 46) For J9325: Report units of service; 1 unit corresponds to 1 million PFU of IMLYGIC® <i>Examples of Billing Units for J9325 for the INITIAL DOSE (1 million PFU per 1 mL vial [10⁶ PFU/mL]):</i> <table border="1"> <thead> <tr> <th>Number of Vials</th> <th>Billing Units</th> <th>11-digit NDC</th> </tr> </thead> <tbody> <tr> <td>1 vial</td> <td>1</td> <td rowspan="4">55513-0078-01</td> </tr> <tr> <td>2 vials</td> <td>2</td> </tr> <tr> <td>3 vials</td> <td>3</td> </tr> <tr> <td>4 vials</td> <td>4</td> </tr> </tbody> </table> Check with payer or Amgen SupportPlus for additional guidance.								Number of Vials	Billing Units	11-digit NDC	1 vial	1	55513-0078-01	2 vials	2	3 vials	3	4 vials	4
Number of Vials	Billing Units	11-digit NDC																	
1 vial	1	55513-0078-01																	
2 vials	2																		
3 vials	3																		
4 vials	4																		
42 REV. CD		43 DESCRIPTION		44 HCPCS / RATE / ICD-9 CODE		45 SERV. DATE													
0636		Drugs/detailed coding		J9325		MMDDYY													
0510		Clinic		9640X		MMDDYY													
46 SERV. UNITS		47 TOTAL CHARGES		48 NON-COVERED CHARGES		49													
X		XXXXX																	
1		XXXXX																	
REVENUE CODE (Box 42) AND DESCRIPTIONS (Box 43) Product Medicare: Use revenue code 0636, drugs requiring detailed coding Other payers: Use revenue code 0250, general pharmacy (or 0636, if required by a given payer) Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic)																			
PROCEDURE CODE (Box 44) Use CPT code representing procedure performed, such as: - 96405, chemotherapy administration; intralesional, up to and including 7 lesions OR - 96406, chemotherapy administration; intralesional, more than 7 lesions Note: If ultrasound guidance is used, the following administration code might be also appropriate: - 76942, ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation																			
50 PAYER NAME		51 HEALTH PLAN ID		52 REL. INFO		53 ASG. BENF.													
54 PRIOR PAYMENTS		55 EST. AMOUNT DUE		56 NPI		57													
OTHER		PRV ID		61 GROUP NAME		62 INSURANCE GROUP NO.													
63		64		65 EMPLOYER NAME		66													
DIAGNOSIS CODES (Box 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis, such as: - C43.0 – C43.9, Malignant melanoma																			
C43.0																			
69 ADMIT DX		70 PATIENT REASON DX		71 PPS CODE		72 ECI													
74 PRINCIPAL PROCEDURE DATE		75 OTHER PROCEDURE DATE		76 ATTENDING		77 OPERATING													
78 OTHER		79 OTHER		80 REMARKS		81													
82		83		84		85													
86		87		88		89													
90		91		92		93													
94		95		96		97													
98		99		100		101													
102		103		104		105													
106		107		108		109													
110		111		112		113													
114		115		116		117													
118		119		120		121													
122		123		124		125													
126		127		128		129													
130		131		132		133													
134		135		136		137													
138		139		140		141													
142		143		144		145													
146		147		148		149													
150		151		152		153													
154		155		156		157													
158		159		160		161													
162		163		164		165													
166		167		168		169													
170		171		172		173													
174		175		176		177													
178		179		180		181													
182		183		184		185													
186		187		188		189													
190		191		192		193													
194		195		196		197													
198		199		200		201													
202		203		204		205													
206		207		208		209													
210		211		212		213													
214		215		216		217													
218		219		220		221													
222		223		224		225													
226		227		228		229													
230		231		232		233													
234		235		236		237													
238		239		240		241													
242		243		244		245													
246		247		248		249													
250		251		252		253													
254		255		256		257													
258		259		260		261													
262		263		264		265													
266		267		268		269													
270		271		272		273													
274		275		276		277													
278		279		280		281													
282		283		284		285													
286		287		288		289													
290		291		292		293													
294		295		296		297													
298		299		300		301													
302		303		304		305													
306		307		308		309													
310		311		312		313													
314		315		316		317													
318		319		320		321													
322		323		324		325													
326		327		328		329													
330		331		332		333													
334		335		336		337													
338		339		340		341													
342		343		344		345													
346		347		348		349													
350		351		352		353													
354		355		356		357													
358		359		360		361													
362		363		364		365													
366		367		368		369													
370		371		372		373													
374		375		376		377													
378		379		380		381													
382		383		384		385													
386		387		388		389													
390		391		392		393													
394		395		396		397													
398		399		400		401													
402		403		404		405													
406		407		408		409													
410		411		412		413													
414		415		416		417													
418		419		420		421													
422		423		424		425													
426		427		428		429													
430		431		432		433													
434		435		436		437													
438		439		440		441													
442		443		444		445													
446		447		448		449													
450		451		452		453													
454		455		456		457													
458		459		460		461													
462		463		464		465													
466		467		468		469													
470		471		472		473													
474		475		476		477													
478		479		480		481													
482		483		484		485													
486		487		488		489													
490		491		492		493													
494		495		496		497													
498		499		500		501													
502		503		504		505													
506		507		508		509													
510		511		512		513													
514		515		516		517													
518		519		520		521													
522		523		524		525													
526		527		528		529													
530		531		532		533													
534		535		536		537													
538		539		540		541													
542		543		544		545													
546		547		548		549													
550		551		552		553													
554		555		556		557													
558		559		560		561													
562		563		564		565													
566		567		568		569													
570		571		572		573													
574		575		576		577													
578		579		580		581													
582		583		584		585													
586		587		588		589													
590		591		592		593													
594		595		596		597													
598		599		600		601													
602		603		604		605													
606		607		608		609													
610		611		612		613													
614		615		616		617													
618		619		620		621													
622		623		624		625													
626		627		628		629													
630		631		632		633													
634		635		636		637													
638		639		640		641													
642		643		644		645													
646		647		648		649													
650		651		652		653													
654		655		656		657													
658		659		660		661													
662		663		664		665													
666		667		668		669													
670		671		672		673													
674		675		676		677													
678		679		680		681													
682		683		684		685													
686		687		688		689													
690		691		692		693													
694		695		696		697													
698		699		700		701													
702		703		704		705													
706		707		708		709													
710		711		712		713													
714		715		716		717													
718		719		720		721													
722		723		724		725													
726		727		728		729													
730		731		732		733													
734		735		736		737													
738		739		740		741													
742		743		744		745													
746		747		748		749													
750		751		752		753													
754		755		756		757													
758		759		760		761													
762		763		764		765													
766		767		768		769													
770		771		772		773													
774		775		776		777													
778		779		780		781													
782		783		784		785													
786		787		788		789													
790		791		792		793													
794		795		796		797													
798		799		800		801													
802		803		804		805													
806		807		808		809													
810		811		812		813													
814		815		816		817													
818		819		820		821													
822		823		824		825													
826		827		828		829													
830		831		832		833													

For Dates of Service on or After 1/1/2017

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.



Billing System

Update billing systems with appropriate billing codes, which may include:

- Updating billing software with the new HCPCS code and appropriate billing unit
- NDC numbers for both dosing concentrations of IMLYGIC®
- CPT codes for intralesional injections
- CPT code for ultrasonic guidance for needle placement

Consider establishing a process for integrating billing systems with additional clinical information, including:

- Number of lesions injected with IMLYGIC® during the visit to help select an appropriate CPT code (ie, ≤7 vs >7 injections)
- Volume of IMLYGIC® used during the visit to help identify appropriate billing units and to document unused drug, if required by payer (ie, volume injected vs volume discarded)

Information that may help billing staff includes:

- Billing considerations for initial vs subsequent doses of IMLYGIC®
- Coding and billing requirements for ultrasound guidance

Claim Submission

Contact Amgen SupportPlus or call the local payer to check specific coding and billing requirements. Consider the following:

- Confirm payer(s) have updated their system with the new HCPCS code
- Billing documentation requirements for discarded volume of IMLYGIC®

Confirm appropriate documentation in the patient's medical record, which may include:

- Clinical documentation to support appropriate E&M code
- Number and location of lesions injected with IMLYGIC® during the visit
- Time of injection(s) for IMLYGIC® and corresponding clinician's signature

References

- Centers for Medicare & Medicaid Services. 2020 Alpha-Numeric HCPCS File. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS-Items/2020-Alpha-Numeric-HCPCS-File> Accessed August 22, 2022.
- American Medical Association. Current Procedural Terminology (CPT®) copyright 2020 American Medical Association. 2021. All Rights Reserved.
- Centers for Medicare & Medicaid website. ICD-10-CM tabular list of diseases and injuries. <https://www.cms.gov/files/zip/2022-code-tables-tabular-and-index-updated-02012022.zip>. Accessed September 1, 2022.
- IMLYGIC® (talimogene laherparepvec) Prescribing Information. Amgen.

The information provided in this Billing and Coding Considerations sheet is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this section be considered a guarantee of coverage or reimbursement for any product or service.



INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitations of use: IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.

IMPORTANT SAFETY INFORMATION

Contraindications

- Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
- Do not administer IMLYGIC® to pregnant patients.

Warnings and Precautions

- **Accidental exposure to IMLYGIC®** may lead to transmission of IMLYGIC® and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. The affected area in exposed individuals should be cleaned thoroughly with soap and water and/or a disinfectant.
- Caregivers should wear protective gloves when assisting patients in applying or changing occlusive dressings and observe safety precautions for disposal of used dressings, gloves, and cleaning materials. Exposed individuals should clean the affected area thoroughly with soap and water and/or a disinfectant.
- To prevent possible inadvertent transfer of IMLYGIC® to other areas of the body, patients should be advised to avoid touching or scratching injection sites or occlusive dressings.
- **Herpetic infections:** Herpetic infections (including but not limited to cold sores and herpetic keratitis) and serious cases of disseminated herpetic infections have been reported in IMLYGIC®-treated patients, including fatal disseminated herpetic infection in the immunocompromised patient population. Immunocompromised patients may be at increased risk of life-threatening disseminated herpetic infection. Patients who develop suspicious herpes-like lesions should follow standard hygienic practices to prevent viral transmission.
- Patients or close contacts with suspected signs or symptoms of a herpetic infection should contact their health care provider to evaluate the lesions. Suspected herpetic lesions should be reported to Amgen at 1-855-IMLYGIC (1-855-465-9442). Patients or close contacts have the option of follow-up testing for further characterization of the infection.

- IMLYGIC® is sensitive to acyclovir. Acyclovir or other antiviral agents may interfere with the effectiveness of IMLYGIC®. Consider the risks and benefits of IMLYGIC® treatment before administering antiviral agents to manage herpetic infection.
- **Injection Site Complications:** Necrosis or ulceration of tumor tissue may occur during IMLYGIC® treatment. Cellulitis and systemic bacterial infection have been reported in clinical studies. Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.
- Impaired healing at the injection site has been reported. IMLYGIC® may increase the risk of impaired healing in patients with underlying risk factors (eg, previous radiation at the injection site or lesions in poorly vascularized areas). If there is persistent infection or delayed healing of the injection site, consider the risks and benefits of continuing treatment.
- **Immune-Mediated events** including glomerulonephritis, vasculitis, pneumonitis, worsening psoriasis, and vitiligo have been reported in patients treated with IMLYGIC®. Consider the risks and benefits of IMLYGIC® before initiating treatment in patients who have underlying autoimmune disease or before continuing treatment in patients who develop immune-mediated events.
- **Plasmacytoma at the Injection Site:** Plasmacytoma in proximity to the injection site has been reported in a patient with smoldering multiple myeloma after IMLYGIC® administration in a clinical study. Consider the risks and benefits of IMLYGIC® in patients with multiple myeloma or in whom plasmacytoma develops during treatment.
- **Obstructive Airway Disorder:** Obstructive airway disorder has been reported following IMLYGIC® treatment. Use caution when injecting lesions close to major airways.
- **Hepatic Hemorrhage from Transcutaneous Intrahepatic Route of Administration:** IMLYGIC® is not indicated for transcutaneous intrahepatic route of administration. In clinical studies, cases of hepatic hemorrhage resulting in hospitalization and death have been reported in patients receiving transcutaneous intrahepatic IMLYGIC® injections.

Adverse Reactions

- The most commonly reported adverse drug reactions (≥ 25%) in IMLYGIC®-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain. Pyrexia, chills, and influenza-like illness can occur at any time during IMLYGIC® treatment, but were more frequent during the first 3 months of treatment.
- The most common Grade 3 or higher adverse reaction was cellulitis.

Please click here to see full [Prescribing Information](#) and [Medication Guide](#) for IMLYGIC®.



Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

© 2023 Amgen Inc. All rights reserved. USA-678-80197 03/23



IMLYGIC®
(talimogene laherparepvec)
SUSPENSION FOR INJECTION
10⁶ PFU/mL and 10⁸ PFU/mL single-use vials